^
    13d
    AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
    P3, N=5949, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    13d
    NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)
    14d
    Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, CStone Pharmaceuticals | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    gemcitabine • oxaliplatin • Cejemly (sugemalimab) • Oncaspar liquid (pegaspargase)
    19d
    AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov)
    P3, N=9350, Completed, Children's Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    21d
    Aggressive NK-cell leukemia with CD5(+)CD10(-) monoclonal B cell lymphocytosis and hemophagocytic lymphohistiocytosis: a case report and literature review (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    The patient was initially treated with etoposide and dexamethasone. After receiving three courses of chemotherapy based on pegaspargase and other combination regimens, the patient's condition deteriorated. Resuscitation treatment was ineffective; the patient died due to multiple organ failure.
    Review • Journal
    |
    CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
    |
    etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase)
    28d
    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=53, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
    1m
    A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Tyvyt (sintilimab) • Xpovio (selinexor) • Oncaspar liquid (pegaspargase)
    1m
    ALLIANCE: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=318, Completed, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine
    1m
    ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Feb 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • CD4 (CD4 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    1m
    Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    gemcitabine • oxaliplatin • Xpovio (selinexor) • Oncaspar liquid (pegaspargase)
    2ms
    Rux-cALL-Pol 2020: Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. (2024-518316-39-00)
    P2/3, N=25, Recruiting, Medical University Of Lodz | Not yet recruiting --> Recruiting
    Enrollment open
    |
    JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    KMT2A rearrangement
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • vindesine
    2ms
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Beijing Tongren Hospital
    New P1/2 trial
    |
    etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)